EUVIMEDEUVIMED entdecken
Open Access

Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus

Catherine A Chappell iD, Jennifer J Kiser, Kristina M Brooks iD, Riley Randolph, Ingrid S Macio, Leslie A Meyn iD, Sam MaWhinney, Anne-Marie Rick, Gysella B Muniz iD, Kyung Min Kwon, Cathleen Letterio, Sarjita Naik und 4 weitere

Clinical Infectious Diseases · 30.04.2025 · 80 (4) · 744-751

DOI: 10.1093/cid/ciae595 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 17.12.2024. Verfasst von Catherine A Chappell und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Sofosbuvir, Heterocyclic Compounds, 4 or More Rings, Antiviral Agents, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment of hepatitis C virus (HCV) during pregnancy can cure maternal HCV and prevent perinatal HCV transmission. The primary objective was to compare the pharmacokinetics (PK) of sofosbuvir (SOF)/velpatasvir (VEL) in pregnant versus nonpregnant people.

Methods

Pregnant people with chronic HCV infection were enrolled between 23 and 25 weeks’ gestation and were provided SOF/VEL daily for 12 weeks. PK visits were performed at 3, 6, and 9 weeks. VEL, SOF, and GS-331007 (the inactive metabolite of SOF) in plasma and the SOF active metabolite (007-TP) in peripheral blood mononuclear cells (PBMCs) and dried blood spots (DBSs) were measured and compared to historical data in nonpregnant people. Maternal adverse events, delivery outcomes, the sustained virologic response 12 weeks after therapy, infant adverse events, and HCV perinatal transmission were assessed.

Results

Fourteen participants were screened, and 11 enrolled. One participant discontinued treatment due to worsening of hyperemesis. VEL area under the curve (AUC) was similar to historic data in nonpregnant people, but the AUCs of SOF and GS-331007 were 38% higher and 38% lower, respectively. Concentrations of 007-TP in PBMCs were comparable or higher, whereas 007-TP in DBSs was approximately 50% lower in pregnant versus nonpregnant people. All 10 participants who completed treatment had undetectable HCV RNA at delivery. Two participants were lost to follow-up after delivery, but 1 had an HCV RNA through clinical care. All participants with data were cured (n = 9) and none of the infants acquired HCV (n = 8).

Conclusions

SOF/VEL exposures were not clinically different in pregnancy and support further evaluation of antenatal SOF/VEL treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SofosbuvirHeterocyclic Compounds, 4 or More RingsAntiviral AgentsPregnancy Complications, InfectiousCarbamatesHepatitis C, ChronicHumansFemalePregnancyAdultHepacivirusInfectious Disease Transmission, VerticalYoung AdultTreatment OutcomeBenzimidazolesBenzopyransDrug Combinations

Stichwörter der Autor:innen

hepatitis C viruspregnancysofosbuvirvelpatasvir

Substanzen

SofosbuvirHeterocyclic Compounds, 4 or More RingsAntiviral AgentsCarbamatesvelpatasvirsofosbuvir-velpatasvir drug combinationBenzimidazolesBenzopyransDrug Combinations

Autor:innen und Institutionen

  • Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA.
  • Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Department of Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Gilead Sciences, Foster City, California, USA.

ORCID-Profile: Catherine A Chappell, Kristina M Brooks, Leslie A Meyn, Gysella B Muniz

Förderung

  • NICHD NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • NIH HHS
  • Gilead Sciences
  • NIH/Office of Research on Women's Health
  • National Institutes of Health
  • NIH/Office of Research on Women’s Health

Zitieren

APA

Chappell, C. A., Kiser, J. J., Brooks, K. M., Randolph, R., Macio, I. S., Meyn, L. A., MaWhinney, S., Rick, A. M., Muniz, G. B., Kwon, K. M., Letterio, C., Naik, S., Kreter, B., Bunge, K. E., Krans, E. E., & Hillier, S. L. (2025). Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clinical Infectious Diseases, 80(4), 744-751. https://doi.org/10.1093/cid/ciae595

Vancouver

Chappell CA, Kiser JJ, Brooks KM, Randolph R, Macio IS, Meyn LA, et al. Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clinical Infectious Diseases. 2025;80(4):744-751. doi:10.1093/cid/ciae595

BibTeX
@article{Chappell2025,
  author = {Chappell, Catherine A and Kiser, Jennifer J and Brooks, Kristina M and Randolph, Riley and Macio, Ingrid S and Meyn, Leslie A and MaWhinney, Sam and Rick, Anne-Marie and Muniz, Gysella B and Kwon, Kyung Min and Letterio, Cathleen and Naik, Sarjita and Kreter, Bruce and Bunge, Katherine E and Krans, Elizabeth E and Hillier, Sharon L},
  title = {Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {80},
  number = {4},
  pages = {744--751},
  doi = {10.1093/cid/ciae595}
}
Kostenlos starten →